Skip to main content
Clinical Trials/NCT05022173
NCT05022173
Active, not recruiting
Not Applicable

Helmet NIV Versus Facemask NIV in Acute Respiratory Failure: A Pilot Randomized Control Trial

Hamilton Health Sciences Corporation1 site in 1 country15 target enrollmentNovember 11, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Respiratory Failure
Sponsor
Hamilton Health Sciences Corporation
Enrollment
15
Locations
1
Primary Endpoint
Recruitment Rate
Status
Active, not recruiting
Last Updated
9 months ago

Overview

Brief Summary

Non-invasive ventilation (NIV) is a form of respiratory support that has been shown to prevent invasive mechanical ventilation and reduce mortality. This study will investigate the feasibility of performing a larger study examining whether a new modality of NIV, the helmet, is superior to the current face mask in reducing mortality in patients with sudden respiratory failure.

Registry
clinicaltrials.gov
Start Date
November 11, 2021
End Date
November 1, 2025
Last Updated
9 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • patients who are admitted to the adult ICU
  • deemed to require NIV, as per the clinical team, for acute respiratory failure.

Exclusion Criteria

  • with impending cardiac arrest or need for intubation
  • Glasgow coma scale \<9
  • tracheostomy or upper airway obstruction
  • elevated intracranial pressure
  • untreated pneumothorax
  • who refuse endotracheal intubation (do not intubate order documented)
  • facial trauma
  • are unable to wear the helmet or facemask
  • who use NIV chronically

Outcomes

Primary Outcomes

Recruitment Rate

Time Frame: 1 year

Number of patients recruited to the study per centre

Consent Rate

Time Frame: 1 year

Percentage of patients or SDMs approached for consent who give consent

Protocol adherence percentage

Time Frame: 1 year

Adherence to pre-specified fixed protocol on how helmet interface is implemented (settings, weaning etc.) Any protocol deviations will be recorded and marked as protocol non-adherence.

Secondary Outcomes

  • Endotracheal intubation(28 days)
  • Hospital mortality(60 days)
  • Duration of invasive ventilation(Censored at 28 days)
  • ICU mortality(28 days)
  • Adverse events(28 days)
  • ICU length of stay(Censored at 28 days)
  • Duration of non-invasive ventilation(Censored at 28 days)
  • Comfort(28 days)
  • Hospital length of stay(Censored at 60 days)

Study Sites (1)

Loading locations...

Similar Trials